Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions

被引:5
作者
Arp, J
Rovinski, B
Sambhara, S
Tartaglia, J
Dekaban, G
机构
[1] John P Robarts Res Inst, Gene Therapy & Mol Virol Grp, London, ON N6A 5K8, Canada
[2] Pasteur Merieux Connaught, Toronto, ON, Canada
关键词
D O I
10.1089/vim.1999.12.281
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Virus-specific cytotoxic T lymphocytes (CTLs) may represent significant immune mechanisms in the control of human immunodeficiency virus (HIV) infection and, therefore, CTL induction may be a fundamental goal in the development of an efficacious acquired immunodeficiency syndrome (AIDS) vaccine. In the current study, prime-boost protocols were used to investigate the potential of noninfectious human immunodeficiency virus type 1 (HIV-1) pseudovirions (HIV PSV) in enhancing HIV-specific CTL responses in Balb/c mice primed with the recombinant canarypox vector, vCP205, encoding HIV-1 gp120 (MN strain) in addition to Gag/Protease (IIIB strain). The prime-boost immunization regimens were administered intramuscularly and involved injections of vCP205 followed by boosts with HIV PSV. Previous vaccination strategies solely involving vCP205 had induced good cellular immune responses in uninfected human volunteers, despite some limitations. The use of genetically engineered HIV PSV was a logical step in the evaluation of whole noninfectious virus or inactivated virus vaccine strategies, particularly as a potential boosting agent for vCP205-primed recipients. Based on this current study, HIV PSV appeared to have the capability to effectively induce and boost cell-mediated HIV-1-specific responses. In order to observe the immune effects of HIV PSV in a prime-boost immunization strategy, both HIV vaccine immunogens required careful titration in vivo. This suggests that careful consideration should be given to the optimization of immunization protocols destined for human use.
引用
收藏
页码:281 / 296
页数:16
相关论文
共 56 条
  • [11] Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults
    Clements-Mann, ML
    Weinhold, K
    Matthews, TJ
    Graham, BS
    Gorse, GJ
    Keefer, MC
    McElrath, MJ
    Hsieh, RH
    Mestecky, J
    Zolla-Pazner, S
    Mascola, J
    Schwartz, D
    Siliciano, R
    Corey, L
    Wright, PF
    Belshe, R
    Dolin, R
    Jackson, S
    Xu, S
    Fast, P
    Walker, MC
    Stablein, D
    Excler, JL
    Tartaglia, J
    Duliege, AM
    Sinangil, F
    Paoletti, E
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) : 1230 - 1246
  • [12] T-CELL PROLIFERATION TO SUBINFECTIOUS SIV CORRELATES WITH LACK OF INFECTION AFTER CHALLENGE OF MACAQUES
    CLERICI, M
    CLARK, EA
    POLACINO, P
    AXBERG, I
    KULLER, L
    CASEY, NI
    MORTON, WR
    SHEARER, GM
    BENVENISTE, RE
    [J]. AIDS, 1994, 8 (10) : 1391 - 1395
  • [13] Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity
    Cole, KS
    Rowles, JL
    Jagerski, BA
    MurpheyCorb, M
    Unangst, T
    Clements, JE
    Robinson, J
    Wyand, MS
    Desrosiers, RC
    Montelaro, RC
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (07) : 5069 - 5079
  • [14] ENHANCED IMMUNITY TO HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) ENVELOPE ELICITED BY A COMBINED VACCINE REGIMEN CONSISTING OF PRIMING WITH A VACCINIA RECOMBINANT EXPRESSING HIV ENVELOPE AND BOOSTING WITH GP160-PROTEIN
    COONEY, EL
    MCELRATH, MJ
    COREY, L
    HU, SL
    COLLIER, AC
    ARDITTI, D
    HOFFMAN, M
    COOMBS, RW
    SMITH, GE
    GREENBERG, PD
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (05) : 1882 - 1886
  • [15] Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
    Corey, L
    McElrath, MJ
    Weinhold, K
    Matthews, T
    Stablein, D
    Graham, B
    Keefer, M
    Schwartz, D
    Gorse, G
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (02) : 301 - 309
  • [16] INDUCTION OF CYTOTOXIC T-LYMPHOCYTES BY RECOMBINANT CANARYPOX (ALVAC) AND ATTENUATED VACCINIA (NYVAC) VIRUSES EXPRESSING THE HIV-1 ENVELOPE GLYCOPROTEIN
    COX, WI
    TARTAGLIA, J
    PAOLETTI, E
    [J]. VIROLOGY, 1993, 195 (02) : 845 - 850
  • [17] INDUCTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOLYTIC T-LYMPHOCYTE RESPONSES IN SERONEGATIVE ADULTS BY A NONREPLICATING, HOST-RANGE-RESTRICTED CANARYPOX VECTOR (ALVAC) CARRYING THE HIV-1(MN) ENV GENE
    EGAN, MA
    PAVLAT, WA
    TARTAGLIA, J
    PAOLETTI, E
    WEINHOLD, KJ
    CLEMENTS, ML
    SILICIANO, RF
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (06) : 1623 - 1627
  • [18] A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
    Evans, TG
    Keefer, MC
    Weinhold, KJ
    Wolff, M
    Montefiori, D
    Gorse, GJ
    Graham, BS
    McElrath, MJ
    Clements-Mann, ML
    Mulligan, MJ
    Fast, P
    Walker, MC
    Excler, JL
    Duliege, AM
    Tartaglia, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) : 290 - 298
  • [19] Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
    Ferrari, G
    Berend, C
    Ottinger, J
    Dodge, R
    Bartlett, J
    Toso, J
    Moody, D
    Tartaglia, J
    Cox, WI
    Paoletti, E
    Weinhold, KJ
    [J]. BLOOD, 1997, 90 (06) : 2406 - 2416
  • [20] Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type I (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160
    Fleury, B
    Janvier, G
    Pialoux, G
    Buseyne, F
    Robertson, MN
    Tartaglia, J
    Paoletti, E
    Kieny, MP
    Excler, JL
    Riviere, Y
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04) : 734 - 738